Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 486 (LINC00486)
- Target
- LINC00486
- Molecular classification
- Long noncoding RNA (lncRNA), Non-coding RNA gene, Other
01
Overview
LINC00486 is a long intergenic non-protein coding RNA (lncRNA), meaning it is a transcript longer than 200 nucleotides that does not encode a protein[1][2][4][5]. It is located on chromosome 2p22, spans ~101 kb, and generates multiple non-coding RNA isoforms[1][2][3]. LINC00486 has gained research interest as a site recurrently targeted by hepatitis B virus integration in intrahepatic cholangiocarcinoma (ICC), suggesting that disruption of this lncRNA may contribute to oncogenesis[1]. Associations in genomic, transcriptomic, and epigenetic datasets link alterations in LINC00486 to various diseases, particularly cancers, though its precise biological role remains to be fully characterized[1][5]. Functional evidence and druggability data are currently lacking, and it is not a canonical drug target. It is annotated in public gene and disease databases but does not encode a protein product[2][3][5][7].
- Other names
- LINC00486Long intergenic non-protein coding RNA 486HGNC:42946NCBI Gene: 285045Ensembl: ENSG00000230876Previous identifiers: GC02P033051, GC02P033053, GC02P032825, GC02P032831, GC02P033271, GC02P033350, GC02P033429, GC02P033516, GC02P033639
02
Mechanism of action
Not applicable; as no drugs target LINC00486, this field is not relevant
03
Biological functions
Putative regulation of gene expressionPossible involvement in chromatin modification and epigenetic regulation (based on lncRNA properties and dataset associations)Other
04
Disease associations
Cancer (notably intrahepatic cholangiocarcinoma, due to recurrent hepatitis B virus (HBV) integration into its locus)Childhood central nervous system embryonal tumor (association reported, not functional causality)Other (potential roles based on GWAS hits, but limited direct evidence)
05
Safety considerations
None reported; there are no reported therapeutic, drug discovery, or pharmacological safety concerns for LINC00486, as it is not a direct therapeutic target
06
Interacting drugs
None reported; no small molecule or biologic drugs known to interact directly with LINC00486
07
Biomarkers
Potential, not established; altered LINC00486 expression or disruption by HBV integration is being studied as a possible biomarker in cancer research, especially for liver tumors
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 486 (LINC00486).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 486 (LINC00486).